ABT · News · 20260826N
Libre Duo Regulatory Approval
ABBOTT LABORATORIES · 2026-08-26 · Importance 38 · Surprise 60 · In source text
Abbott received FDA authorization on August 26, 2026, for the Libre Duo 10 Day system, the first biowearable designed to continuously sense both glucose and ketones. The device is intended to alert people with diabetes to rising ketone levels associated with diabetic ketoacidosis. The authorization expands Abbott’s FreeStyle Libre diabetes technology franchise and supports its medical-technology portfolio, although no revenue or profit impact was disclosed.
Key facts
- Abbott has received FDA authorization for its Libre Duo 10 Day system. source
- The Libre Duo 10 Day system is described as the world's first dual glucose-ketone sensing technology. source
- The Libre Duo biowearable is designed to alert people with diabetes to rising ketone levels, which can lead to diabetic ketoacidosis (DKA). source
- The Libre Duo system monitors both glucose and ketones continuously. source
- Abbott's approval for the Libre Duo dual glucose sensor was announced on August 26, 2026. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | — | Abbott has received FDA authorization for its Libre Duo 10 Day system. |